-
WuXi Biologics Removed from US Unverified List Amid Ongoing Restrictions
•
The US Commerce Department’s Bureau of Industry and Security (BIS) has updated its Unverified List (UVL), removing WuXi Biologics (HKG: 2269), a contract research organization (CRO) based in Wuxi, China. However, the US authorities have added 31 additional Chinese companies and universities to the list, including Shanghai Tech University, University…
-
India Launches Anti-Dumping Investigation Against Chinese Imports of Metronidazole
•
The Union Ministry of Commerce and Industry in India has initiated an anti-dumping investigation into imports of the antibiotic metronidazole, following a complaint filed by Aarti Drugs Ltd., one of the largest manufacturers of the drug in the country. Complaint DetailsAarti Drugs alleges that Chinese companies aredumping metronidazole at prices…
-
China’s NMPA Proposes Reforms to Enhance Radiopharmaceutical Review and Approval
•
China’s National Medical Products Administration (NMPA) has released a draft proposal titled “Opinions on Reforming and Improving the Administration of Review and Approval of Radiopharmaceuticals,” seeking public feedback. The document outlines a series of reforms aimed at enhancing the regulatory framework for radiopharmaceuticals in the country. Expanding Expertise in Radiopharmaceutical…
-
Ark Biosciences’ Ziresovir Shows Positive Results in Phase III AIRFLO Study for RSV Infection
•
China-headquartered Ark Biosciences has announced positive results from the Phase III AIRFLO study for its novel antiviral drug ziresovir (AK0529). The study evaluated the efficacy and safety of ziresovir in hospitalized infants with respiratory syncytial virus (RSV) infection. The drug achieved its primary endpoint of a significant reduction in symptom…
-
Pfizer’s Talzenna Shows Positive Results in Phase III TALAPRO-2 Study for mCRPC
•
US-based pharmaceutical giant Pfizer (NYSE: PFE) has announced positive results from the Phase III TALAPRO-2 study for its oral poly ADP ribose polymerase (PARP) inhibitor, Talzenna (talazoparib). The study evaluated the drug in combination with Xtandi (enzalutamide) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) with or without homologous…
-
Hua Medicine’s Dorzagliatin Approved in China for Type 2 Diabetes
•
China-based Hua Medicine (HKG: 2552) has announced that its Category 1 drug dorzagliatin has been approved by the National Medical Products Administration (NMPA) for improving blood glucose control in adults with type 2 diabetes. The first-in-class oral hypoglycemic drug represents an innovative treatment option for patients in China. Approval Based…
-
Allergan Aesthetics Launches Juvederm Volite in China’s Boao Lecheng
•
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), has announced the commercial launch of Juvederm Volite at the Arsmo (Hainan) Aesthetic Hospital in Boao Lecheng, China. The product follows the successful introduction of Juvederm Volux into the region under the “first pilot, first trial” policy, further expanding the company’s aesthetic portfolio…
-
Shanghai Lange Medtech Partners with Yantai Desheng for Fish-Derived Rotator Cuff Patch
•
China-based Shanghai Lange Medtech Co., Ltd. has entered into a partnership with compatriot firm Yantai Desheng Marine Biotechnology Co., Ltd. to develop a fish-derived rotator cuff biological patch. The collaboration will also focus on constructing the largest fish-derived acellular matrix preparation technology platform in China and advancing clinical and scientific…
